Alirocumab is a human monoclonal antibody designed for the treatment of hypercholesterolemia. This therapeutic is also known by the codes REGN727 and SAR236553.
This drug was discovered by Regeneron Pharmaceuticals and is being co-developed by Regeneron and Sanofi.
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization
- ^ Sheridan, C (2013). "Phase 3 data for PCSK9 inhibitor wows". Nature Biotechnology 31 (12): 1057–8. doi:10.1038/nbt1213-1057. PMID 24316621.